Disease

Fatty Liver, Alcoholic

Active therapeutic pipelineEmerging research

MeSHFatty Liver, Alcoholic

Publications

Clinical trials

2020

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases.

Research2020-01-01Hepatology (Baltimore, Md.)

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

1 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Recruiting

Randomized Comparative Clinical Study of the Dietary Supplement "Gepaktiv" (International Name: Phenomenon) in Comparison With Ursodeoxycholic Acid (UDCA) and Ademetionine in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) and Hepatomegaly

N/A · Recruiting · Phenomen Pharma

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases.

Hepatology (Baltimore, Md.) · 2020 · 617 cites

Recent publications

Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases.

Hepatology (Baltimore, Md.) · 2020 · 617 cites

Leading journals1

Hepatology (Baltimore, Md.)1

Leading researchers5

Crabb DW1
Im GY1
Lucey MR1
Mellinger JL1
Szabo G1

Affiliations (unnormalised)5

Icahn School of Medicine at Mount Sinai1
Indiana University School of Medicine1
University of Massachusetts Medical School1
University of Michigan Hospitals & Health Centers1
University of Wisconsin School of Medicine1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated.

Identifiers

MeSHFatty Liver, Alcoholic

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.